Comparative Pharmacology
Head-to-head clinical analysis: TAGAMET versus TAGAMET HB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAGAMET versus TAGAMET HB.
TAGAMET vs TAGAMET HB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, inhibiting gastric acid secretion. Also reduces pepsin and intrinsic factor secretion.
Competitive antagonist at histamine H2 receptors, inhibiting gastric acid secretion by blocking the action of histamine on parietal cells in the stomach.
400 mg orally twice daily or 800 mg orally at bedtime for duodenal ulcer; 300 mg IV/IM every 6-8 hours.
200-400 mg orally twice daily or 800 mg orally at bedtime.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (normal renal function); prolonged to 5-10 hours in moderate renal impairment (CrCl <30 mL/min) and up to 20-30 hours in anuria
2–3 hours (normal renal function), prolonged to 5–6 hours in moderate renal impairment, up to 20 hours in severe impairment; requires dose adjustment in CrCl <30 mL/min.
Renal: 50-70% unchanged; hepatic metabolism: ~30%; biliary/fecal: minor (<5%)
Renal (70% unchanged via glomerular filtration and tubular secretion), fecal (less than 10%), biliary (minor).
Category C
Category C
H2 receptor antagonist
H2 receptor antagonist